A PHASE 3 RANDOMIZED STUDY COMPARING JNJ-79635322 AND AN ANTI-BCMAXCD3 BISPECIFIC ANTIBODY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 3 PRIOR LINES OF THERAPY INCLUDING A PI, AN IMID, AND AN ANTI-CD38 ANTIBODY

Registry ID

79635322MMY3001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

JANSSEN INC

Start date

2026-04-09

Last update

2026-03-05

Conditions

• RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Related clinical trials

• A PHASE III OPEN-LABEL, RANDOMISED, MULTICENTRE STUDY COMPARING AZD0120, A DUAL-TARGETING AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DIRECTED AGAINST BCMA AND CD19, VERSUS STANDARD REGIMENS IN PARTICIP WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (DURGA-4)
• A PHASE 1B/2A, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND SCHEDULE, AND EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF MEZIGDOMIDE IN COMBINATION WITH ELRANATAMAB IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
• A PHASE 1/2 STUDY OF ETENTAMIG IN COMBINATION WITH A CELMOD AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF ANITOCABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
• A FIRST-IN-HUMAN, OPEN-LABEL, PHASE 1 STUDY TO EVALUATE THE SAFETY, ANTITUMOR ACTIVITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS SAR446523, AN ANTI GPRC5D ADCC-ENHANCED MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
• A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF BMS-986393, A GPRC5D-DIRECTED CAR T CELL THERAPY IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (QUINTESSENTIAL)

View on source registry